We maintain our BUY recommendation on BDMS with a 2027 target price of THB 25.00/share based on DCF valuation. We believe the CARIVA deal strengthens BDMS's competitive position through: Greater exposure to Healthcare AI and Digital Health Improved operating efficiency and cost optimization. Expansion opportunities into higher-growth HealthTech businesses Long-term earnings and valuation upside through technology-driven healthcare services

Attached Documents :

BDMS261103.pdf